Abstract: An energy storage system comprising at least one energy storage module adapted to supply electrical energy to a hybrid vehicle. The energy storage module comprises an enclosure, at least one battery array located within the enclosure, and an energy storage controller module located within the enclosure and electrically connected to the battery array. The energy storage module further comprises a compliant tipped thermistor which may be installed within a flexible clip. The thermistor is positioned to monitor the temperature of one or more of the batteries within the energy storage system.

Abstract: Disclosed herein is a method of inhibiting T Follicular Helper (TFH) cell-mediated differentiation and/or activation in a subject. This method involves administering to a subject in need of treatment for an autoimmune disorder a eukaryotic translation initiation factor 4E (eIF4E) inhibitor to inhibit TFH cell-mediated differentiation and/or activation in the subject. Also disclosed is a method of inhibiting T Follicular Helper (THF) cell differentiation or TFH cell activity.

Abstract: A laundry appliance includes a cabinet defining a front opening in a front panel. The front opening is defined by a lip having a curved edge. The lip defines a plurality of apertures spaced-apart around the front opening. A tub is disposed within the cabinet. The tub defines an access opening aligned with the front opening. A drum is disposed within the tub. A bellows assembly extends between the cabinet and the tub. The bellows assembly includes a projection coupled to the curved edge of the cabinet. A deflector has a rim and a chute wherein the chute extends toward the drum. The rim is configured to snap-fit over the projection of the bellows assembly. The rim includes a plurality of hooks where each hook is configured to extend through an aperture and interlock with the cabinet.

Abstract: A laundry appliance includes a cabinet defining a front opening in a front panel. The front opening is defined by a lip having a curved edge. The lip defines a plurality of apertures spaced-apart around the front opening. A tub is disposed within the cabinet. The tub defines an access opening aligned with the front opening. A drum is disposed within the tub. A bellows assembly extends between the cabinet and the tub. The bellows assembly includes a projection coupled to the curved edge of the cabinet. A deflector has a rim and a chute wherein the chute extends toward the drum. The rim is configured to snap-fit over the projection of the bellows assembly. The rim includes a plurality of hooks where each hook is configured to extend through an aperture and interlock with the cabinet.

Abstract: Aspects of the technology are directed to a method of increasing sensitivity of estrogen receptor positive (ER+) breast cancer cells to treatment with an endocrine therapy. The method involves selecting ER+ breast cancer cells, and administering to the selected cells (i) one or more mammalian target of rapamycin (mTOR) inhibitors and (ii) one or more MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1) inhibitors in an effective amount to increase the sensitivity of the ER+ breast cancer cells to treatment with the endocrine therapy. Methods of treating a subject having ER+ breast cancer are also disclosed.

Abstract: Disclosed herein is a method of inhibiting T Follicular Helper (TFH) cell-mediated differentiation and/or activation in a subject. This method involves administering to a subject in need of treatment for an autoimmune disorder a eukaryotic translation initiation factor 4E (eIF4E) inhibitor to inhibit TFH cell-mediated differentiation and/or activation in the subject. Also disclosed is a method of inhibiting T Follicular Helper (THF) cell differentiation or TFH cell activity.

Abstract: The present application relates to an adeno-associated viral (AAV) vector, comprising a muscle cell-specific promoter and a nucleic acid molecule encoding an AU-rich mRNA binding factor 1 (AUF1) protein or a functional fragment thereof, where the nucleic acid molecule is heterologous to and operatively coupled to the muscle cell-specific promoter. Also disclosed are compositions comprising the AAV vector, as well as methods of promoting muscle regeneration in injured muscle, a method of treating degenerative skeletal muscle loss in a subject, methods of preventing traumatic muscle injury in a subject such as Duchenne Muscular Dystrophy, methods of treating traumatic muscle injury in a subject, and methods of treating muscle loss due to aging in a subject.

Abstract: A laundry appliance includes a cabinet defining a front opening in a front panel. The front opening is defined by a lip having a curved edge. The lip defines a plurality of apertures spaced-apart around the front opening. A tub is disposed within the cabinet. The tub defines an access opening aligned with the front opening. A drum is disposed within the tub. A bellows assembly extends between the cabinet and the tub. The bellows assembly includes a projection coupled to the curved edge of the cabinet. A deflector has a rim and a chute wherein the chute extends toward the drum. The rim is configured to snap-fit over the projection of the bellows assembly. The rim includes a plurality of hooks where each hook is configured to extend through an aperture and interlock with the cabinet.

Abstract: Aspects of the technology are directed to a method of increasing sensitivity of estrogen receptor positive (ER+) breast cancer cells to treatment with an endocrine therapy. The method involves selecting ER+ breast cancer cells, and administering to the selected cells (i) one or more mammalian target of rapamycin (mTOR) inhibitors and (ii) one or more MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1) inhibitors in an effective amount to increase the sensitivity of the ER+ breast cancer cells to treatment with the endocrine therapy. Methods of treating a subject having ER+ breast cancer are also disclosed.

Abstract: The present invention relates to compositions (e.g., AUF1 encoding compositions) for muscle cell uptake, satellite cell populations and compositions containing muscle satellite cell populations, pharmaceutical compositions, methods of producing muscle satellite cell compositions, and methods of causing muscle satellite cell mediated muscle generation.

Abstract: An appliance includes an appliance for the home-brewing of beer that includes a brewing unit including a heating unit, a recirculation pump, a first steeping chamber having an inlet and a flow-controlled outlet, a supply line in fluid communication with the inlet, and a collector in fluid communication with the outlet. The recirculation pump has a draw line in fluid communication with the collector. The appliance further includes a fermenting unit physically separate from the brewing unit and having a vessel adjacent a temperature control assembly. The fermenting unit is selectively fluidically coupleable with the brewing unit for transfer of fluid from the brewing unit to the fermenting unit and fluidically decouplable from the brewing unit.

Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

Abstract: Example embodiments are directed to a method of fuel bundle design, core design, or combined fuel and core design, to ensure Pellet Cladding Interaction (PCI) related fuel failures are mitigated. More specifically, example embodiments provide fuel and/or core designs that may be determined prior to operation of a nuclear power plant, or prior to production of fresh fuel bundles. The PCI optimized fuel/core designs may include some or all of seven PCI Evaluation Methods which may be incorporated into existing nuclear reactor simulation programs. PCI optimized fuel and/or core design enhances fuel reliability, allows faster beginning-of-cycle (BOC) startups and faster middle-of-cycle (MOC) sequence exchanges to maximize plant performance, and minimizes ramping restrictions, thereby maximizing nuclear power plant performance.

Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.

Abstract: The present invention relates to a novel Ad based packaging system that can be used for incorporation of heterologous DNA into infectious but replication defective viral particles. The components of the invention include an “artificial genome”, i.e., a recombinant vector which contains elements that function as adenovirus replication and packaging signals flanking an intervening DNA sequence. The elements may comprise the minimum genomic Ad sequences required to direct replication of heterologous DNA and packaging into viral particles. The system also includes a means for expressing complementing helper functions to provide in trans viral proteins required for replication and packaging of recombinant viral vectors, but without contaminating the stock of recombinant, trans-packaged viral particles.

Abstract: An appliance lift tool is provided which includes a support platform having a horizontal orientation, a bottom frame, a lift mechanism engaged between the support platform and the bottom frame to move the support platform toward and away from the bottom frame, while maintaining the support platform's horizontal orientation, and at least three feet extending below the bottom frame, with the feet being positioned outside of a perimeter of the support platform.

Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.